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Many efforts have been dedicated to identify an adequate tumour
marker in the serum of patients with squamous cell carcinoma 
of head and neck (HNSCC), which would allow for simple non-
invasive follow up of these patients. Unfortunately, there is no
known reliable tumour marker for HNSCC. Detection of recurrent
disease among these patients is entirely dependent on clinical
criteria: symptoms, physical examination and radiological studies
such as CT scan and MRI. However, the ability of the clinician to
detect recurrent cancer in head and neck cancer patients after
radiotherapy or surgery to the head and neck at an early stage is
severely limited. Recurrent disease is often deep seated and
obscured by soft tissue and bone that often is altered by radiation
and surgical damage. 
Although several serum tumour markers were tested in
HNSCC, none have proven to be clinically beneficial. Early
studies reported very low sensitivity of various markers like CEA
(carcinoembryonic antigen) (Silverman et al, 1976; Walther et al,
1990), Lipid associated sialic acid (Katopodis et al, 1982; Ropka
et al, 1991) and SCC-marker (TA-4) (Calsen et al, 1990; Daver et
al, 1990; Fichbach et al, 1990; Walther et al, 1990; Yoshimura et
al, 1990; Ropka et al, 1991) in head and neck cancer patients.
Cyfra 21-1 was reported as a new marker for non-small cell carci-
noma of the lung (Pujol et al, 1993; Stieber et al, 1993; Rastel
et al, 1994). For SCC of the lung, the sensitivity was 60% and
specificity was 95%. In non-small cell lung cancer, especially
squamous cell carcinoma, Cyfra 21-1 was found to be a prognostic
indicator. Patients with a serum level of Cyfra 21-1 above an
arbitrary defined cut-off had a significantly shorter overall
survival than those with Cyfra 21-1 below the cut-off (Pujol et al, 
1993). 
In a preliminary study with small group of patients with
HNSCC, Cyfra 21-1 levels were found to be higher in patients
with squamous cell carcinoma of head and neck than in patients with
benign tumours of head and neck, in primary detection of the
disease. The sensitivity and specificity of the marker were 60%
and 94%, respectively. Positive and negative predictive values
were 75% and 89% (Doweck et al, 1995). 
Despite the high levels of Cyfra 21-1 at the time of the initial
diagnosis of head and neck cancer, its prognostic value in a long-
term follow-up has never been proven. More than that, the sensi-
tivity and the mean lead-time of the marker in detecting recurrent
cancer of head and neck, were not previously reported. 
Cyfra 21-1 is a cytokeratin 19 fragment that is recognized by 
the two monoclonal antibodies BM 19-21 and KS 19-1, which
were obtained by immunization of mouse with MCF-7 cells
(Bodenmuller et al, 1992). Cytokeratin 19 is an acid-type cyto-
keratin, with a molecular weight of 40 000 d, and it is released into 
the serum in the form of soluble fragments. It is a cytoplasmatic
protein, one of the cytokeratins which form the intermediate fila-
ment cytoskeleton within epithelial cells (Moll et al, 1982; Osborn
and Weber, 1982). The cytokeratins appear to be distributed in the
various epithelia, according to the cell differentiation (Hoefler and
Derk, 1984). During the malignant transformation, the epithelial
cells appear to contain the same cytokeratins as do normal cells.
The simple epithelium contains cytokeratins 8, 9, 18 and 19 (Moll
et al, 1982). 
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Summary This study examines a new tumour marker, Cyfra 21-1, as a prognostic marker in predicting the survival of H&N cancer patients, and
its correlation with clinical outcome during prolonged follow up of these patients. The study included 67 patients with primary detection of
carcinoma of H&N. The survival of these patients was evaluated in correlation with the disease stage and Cyfra 21-1 levels at initial diagnosis.
38 patients were followed clinically and with serial assays for at least 12 months, or until recurrence was diagnosed. Cyfra 21-1 levels were
determined periodically, using an Elisa kit. Patients with Cyfra 21-1 < 1.5 ng ml–1 had a higher survival rate compared to patients with Cyfra 21-1
≥ 1.5 ng ml–1 (63% vs. 20%, respectively). The risk ratio of Ln(Cyfra 21-1) is 1.62 (P = 0.028). In a Cox regression model that included the disease
stage and Ln(Cyfra 21-1), Ln(Cyfra 21-1) was preferred as the main parameter for predicting patients survival. In 83% of the 12 patients with
recurrent or residual disease, Cyfra 21-1 was elevated before or during clinical detection of the recurrence. Cyfra 21-1 was found to be a
prognostic marker for carcinoma of H&N, unrelated to the stage of the disease. Elevated levels of Cyfra 21-1 without clinical evidence of disease
can be attributed to the marker’s mean lead-time as compared to the clinical appearance of the disease. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1502, available online at http://www.idealibrary.com on  http://www.bjcancer.comIn the present study, we correlated the expression of the serum
marker Cyfra 21-1 at the initial diagnosis with the survival rate of
head and neck cancer patients, and we evaluated the detection of
recurrence of cancer by repeated blood samples during long term
follow-up. The present study also determined the mean lead-time
between the elevation of the marker and the clinical detection of
recurrence among disease-free patients undergoing serial assays
during follow-up. 
PATIENTS AND METHODS 
Patients 
The study was prospective, and included 67 patients with cancer of
head and neck, untreated previously. The histological diagnosis
revealed squamous cell carcinoma in 57 patients and adeno-
carcinoma in 5 patients. (Other histological diagnoses included:
mucoepidermoid carcinoma, adenoid cystic carcinoma, and un-
differentiated carcinoma.) The sites of origin of the tumors are:
larynx – 34 patients, carcinoma with unknown primary – 9
patients, nasopharynx – 6 patients, parotid gland – 6 patients, nose
and paranasal sinuses – 4 patients, oropharynx – 3 patients, ear – 3
patients and oral cavity – 2 patients. 
The stage of the disease was determined using the TNM
classification according to the American Joint Committee of
Cancer’s (AJCC) staging system. The T staging of the pa-
tients was: T1 – 16 patients, T2 – 13 patients, T3 – 18 patients, T4
– 11 patients, Tx (primary tumour cannot be assessed) – 9 patients.
The N staging was: N0 – 37 patients, N1 – 4 patients, N2 – 21 pa-
tients, N3 – 5 patients. The stage of the disease: stage 1 – 15
patients, stage II – 9 patients, stage III – 9 patients, stage IV – 34
patients. 
Blood samples for Cyfra 21-1 levels were collected after
informed consent was obtained, and before treatment was started. 
Cyfra 21-1 
Cyfra 21-1 was evaluated using an ELISA kit (Elsa Cyfra 21-1
IRMA Kit, CIS Biointernational, Gif-SurYvette, France). 
The mean, standard deviation, median, and range of Cyfra 21-1
level at the various T, N, and stage classifications are shown in
Table 1. 
Survival rates 
The correlations between Cyfra 21-1 levels at initial diagnosis 
and the survival rates of the patients were evaluated using the
following parameters: 
1. Patient status – alive or dead – obtained from official govern-
ment records. 
2. Duration of follow up (from the time of diagnosis). 
3. Cyfra 21-1 levels at the time of initial diagnosis. A loga-
rithmic transformation of the parameter Cyfra 21-1,
Ln(Cyfra) was used for further analysis. 
4. The stage of the disease at initial diagnosis. 
Follow-up and detection of recurrent disease 
For the evaluation of Cyfra 21-1 as an early indicator of recurrent
disease, the patients were followed up throughout the treatment
period regardless of the treatment category. Follow-up was carried
out every month during the first year after diagnosis, and every 3
months in the following years. Follow-up included history, phys-
ical examination and blood samples of 5 ml each for determination
of Cyfra 21-1 levels. Clinical suspicion of recurrence was further
investigated by diagnostic tools such as CT scan or MRI, and
biopsy was done to confirm the diagnosis. If significant increase 
of Cyfra 21-1 levels (>25% from the previous marker level) was
detected without clinical evidence of recurrent disease, blood
sample was repeated. If the elevation in the marker level was 
constant, patients were further investigated by non-invasive
diagnostic tools (radiography, CT, etc.). 
Only patients with follow-up of more than 12 months were
included in this analysis. These included 38 patients. (Of the initial
group of 67 patients, 11 patients suffered from progressive disease
and they died of the disease within the first year of follow up, 4
patients were followed without using this marker, and 14 patients
were followed-up for less than 12 months until the end of the
study.) 
Statistical analysis 
The survival rates were estimated using the Kaplan–Meier survival
table, both in relation to Cyfra 21-1 levels and to the stage of the
disease, and the differences between the curves in each survival
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Table 1 Cyfra 21-1 levels (mean, standard deviation [SD], median, and range [ng/ml]) in correlation to the different
staging subgroups: T1–4, Tx – primary tumour cannot be assessed, N0–3, and Stage I–IV
Cyfra 21-1 (ng ml–1) T1 (n = 16) T2 (n = 13) T3 (n = 18) T4 (n = 11) Tx (n = 9) 
Mean 1.34 2.31 2.24 2.91 4.23 
SD 0.68 4.06 1.81 1.56 6.65 
Median 1.20 1.05 1.70 2.20 1.50 
Range 0.43–2.8 0.33–15.7 0.2–6.6 0.92–5.9 0.8–21 
N0 (n = 37) N1 (n = 4) N2 (n = 21) N3 (n = 5)
Mean 1.87 1.60 2.52 6.70 
SD 2.55 0.48 1.81 8.44 
Median 1.25 1.75 1.85 2.40 
Range 0.2–15.7 0.92–2 0.72–6.6 0.9–21 
Stage I (n = 15) Stage II (n = 9) Stage III (n = 9) Stage IV (n = 34) 
Mean 1.24 2.73 1.73 3.03 
SD 0.58 4.90 1.12 3.67 
Median 1.15 1.05 1.70 1.88 
Range 0.43–2.5 0.33–15.7 0.2–4.3 0.45–21 
n – number of patients in each subgroup.table were obtained using the Log Rank test. A Cox regression
model was used once to evaluate the risk ratio between low and
high levels of Cyfra 21-1, and a second time to include both the
stage of the disease and the Ln(Cyfra 21-1) variables. The defini-
tion of low and high Cyfra 21-1 levels was according to cut-off,
1.5 ng ml–1, for which the sensitivity and specificity are 55% and
96%, respectively; positive predictive value and negative pre-
dictive values are 79% and 89%, respectively. Low Cyfra 21-1 
was Cyfra 21-1 <1.5 ng ml–1, while high level was Cyfra 21-1 
≥ 1.5 ng ml–1. 
The statistical analysis was performed using SPSS software for
Windows. 
RESULTS 
The study included 67 patients, 56 male and 11 female, whose
mean age was 64 ± 13 years (median 64, range 37–90 years). The
patients were followed-up for a mean time of 18 ± 11.7 months,
(median 15; range 1–44 months). Mean follow up duration for sur-
viving patients (38 patients) was 21.6 ± 12.5 months (median 20.5;
range 1–44 months), and 13.6 ± 8.9 months (median 12; range
2–37 months) for 29 terminally ill patients. 
32 patients had low levels of Cyfra 21-1 at diagnosis (< 1.5 ng
ml–1), 23 of them (72%) are alive and 9 (28%) died. 35 patients had
high levels of Cyfra 21-1 (≥ 1.5 ng ml–1) at diagnosis; of these, 15
are alive (43%) and 20 died (57%). 
Survival rates 
Figure 1 presents the survival rate of all the patients included in the
study. Using the Kaplan–Meier survival table, Figure 2 compares
cumulative survival rates of patients with low and high Cyfra 21-1
levels. According to Figures 1 and 2, the survival rate of all pa-
tients is 37% for 44 months. Patients with Cyfra 21-1 levels below
1.5 ng ml–1 had a survival rate of 63% for 44 months, in com-
parison with a 20% survival rate for those with Cyfra 21-1 levels
exceeding 1.5 ng ml–1. These differences are borderline signifi-
cant: P = 0.055 in the Log Rank test. 
A Cox regression model for evaluating the risk ratio between
low and high levels of Cyfra 21-1 using Ln(Cyfra 21-1) found the
Odd’s ratio of Ln(Cyfra 21-1) to be 1.62, which is significant 
(P = 0.028). 
The survival rate according to the stage of the disease is shown
in Figure 3. According to the Kaplan–Meier survival table, pa-
tients in stages I and II had a survival rate of 60% for 44 months, in
comparison with a 24% survival rate over 44 months in subjects 
in stages III and IV. The differences are borderline significant: 
P = 0.06 in the Log Rank test. 
A Cox regression was performed in which the stage of the
disease and Ln(Cyfra 21-1) levels were included. This model
found that both the stage and the Ln(Cyfra 21-1) are related to
survival. However, the Cox Regression model prefers Ln(Cyfra
21-1) as the main parameter for predicting the survival of patients
with carcinoma of H&N, with P = 0.047. 
Follow up and detection of recurrent disease 
38 patients were followed clinically and biochemically for over 12
months, or until recurrence was diagnosed. During the extended
follow up, 14 patients died. The mean time of follow up of all 38
patients was 23.4 ± 10.2 months; for surviving patients 26.6 ± 10
months; for terminal patients 17.9 ± 8.2 months. 
12 (31.6%) of the 38 patients were diagnosed with recurrent 
or residual disease. 26 (68.4%) patients showed no evidence of
disease during the follow-up period. 10 (83%) of the 12 patients
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Figure 1 Cumulative survival rates of all patients 
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Figure 2 Survival rates of patients with high (≥ 1.5 ng ml–1) and low
(< 1.5 ng ml–1) Cyfra 21-1 levels 
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Figure 3 Cumulative survival rates of patients with disease at stages I and
II compared to patients at stages III and IV with recurrent disease showed significant elevation of Cyfra 
21-1 levels before or concomitantly with diagnosis of recurrent or
residual disease. Of the 12 patients with recurrent disease, 50%
showed elevated Cyfra 21-1 levels before the clinical detection 
of the disease, 33% of the patients had elevated marker levels
concomitantly with the clinical detection. The mean time between
the elevation of the marker and the diagnosis of clinical recurrence
(mean lead-time) was 4.1 ± 3.4 months. In two patients (17%) with
clinical evidence of recurrent disease, Cyfra 21-1 levels were not
elevated at the time of diagnosis of the recurrence. The two
patients had nothing in common except the low initial levels of
Cyfra 21-1. Table 2 summarizes the clinical data, Cyfra 21-1
levels, and the lead-time between the elevation in the marker level
and the diagnosis of recurrent disease in these patients. 
26 patients showed no evidence of disease for at least 12 months
of follow up. In 20 of them (77%), there was no significant eleva-
tion in marker levels during follow up. In radiated patients there
was constant elevation in marker levels, both during treatment and
up to 2–3 months after treatment was completed. 4 patients (15%)
exhibited no evidence of disease, but a fluctuation in the marker
levels was noted. None of them had a constant elevation. Two
patients (15%) who exhibited no clinical evidence of the 
disease had a significant elevation of Cyfra 21-1 and died shortly
thereafter. 
DISCUSSION 
Elevated levels of Cyfra 21-1 in previously untreated patients with
head and neck cancer were reported in few studies. Our prelimi-
nary data showed high levels of Cyfra 21-1 in HNSCC (Doweck
et al, 1995). The sensitivity of the marker in nasopharyngeal
carcinoma was found to be 58.3% (Yen et al, 1998). Ogawa et al
reported 41.7% sensitivity of Cyfra 21-1 in patients with HNSCC
(Ogawa et al, 1999). However, the prognostic value of Cyfra 21-1
levels in a long-term follow up of these patients was not reported
before. 
In the present study we found that patients with Cyfra 21-1
levels below 1.5 ng ml–1 had a higher survival rate, 63%, compared
to 20% for patients whose Cyfra 21-1 levels were above 1.5 ng ml–1.
The Odd’s ratio is 1.62 for the logarithmic transformation of Cyfra
21-1, Ln (Cyfra 21-1). Elevation of 1 Ln (Cyfra 21-1), which is
equivalent to elevation of Cyfra 21-1 levels by ~2.7 fold, increases
the death risk by 62%. 
The prognostic value of Cyfra 21-1 was reported previously in
non-small cell lung cancer, especially in SCC, by Pujol et al (Pujol
et al, 1993), who found that patients with a serum Cyfra 21-1 level
above cut-off had a significantly shorter overall survival than those
with a normal serum level. Similar findings were reported by
Niklinski et al (Niklinski et al, 1995), and by Ebert and colleagues
(Ebert et al, 1995). As shown in this study, Cyfra 21-1 is the serum
tumour marker with the most accurate prognostic value for
patients of carcinoma of head and neck. 
Staging of the disease by the TNM classification according 
to the AJCC is accepted worldwide. In addition to providing 
important clinical guidelines, the TNM classification has a well-
established prognostic value. In the present study, the TNM classi-
fication was again found to be a prognostic factor in cancer of the
head and neck. Interestingly, Cyfra 21-1 level (in a logarithmic
transformation) was found to be the main parameter for predicting
survival in this group of patients. This finding was unexpected;
however, the correlation between the serum Cyfra 21-1 level and
the survival rate was expected. A previous study found that Cyfra
21-1 levels were indeed correlated to the extent of the disease, as
expressed by the T and N classifications in squamous cell carci-
noma of head and neck (Doweck et al, 1995). However, in our
study, the prognostic value of Cyfra 21-1 is independent of the
stage of the disease. Our findings are in agreement with those of
Pujol et al (Pujol et al, 1993, 1996), who report that the prognostic
significance obtained by Cyfra 21-1 in squamous cell lung cancer
is independent and adds to the information obtained from other
classic prognostic factors, such as extent of the disease, weight
loss, performance status, etc. Niklinski and colleagues report that
Cyfra 21-1 may be an independent prognostic parameter of
survival and tumour relapse in squamous cell lung cancer
(Niklinski et al, 1996). 
Cyfra 21-1, as reported before, is a soluble fragment of cyto-
keratin 19. The assumption is that Cyfra 21-1 is released into the
bloodstream during cell death, and therefore its level correlates
very well with the tumour mass, or more specifically with the
necrosis in the tumour, which is a function of the tumour mass.
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Table 2 The clinical data of the patients with recurrent disease including: the site of origin of the disease, histology, TNM, stage, Cyfra 21-1 level at the initial
diagnosis, after treatment and at recurrence and the mean lead time between the elevation of the marker level and the clinical diagnosis of the recurrent disease. 
Patient Site Histology TNM Stage Cyfra 21-1 at Treatment Cyfra 21-1 after  Cyfra 21-1 at  Lead time 
diagnosis treatment  recurrence  (months) 
(ng ml–1) (ng ml–1) (ng ml–1)
A.J. Glottis SCC, wd T3N2M0 IV 1.9 Surgery + RT 1.0 1.6 0 
M.Z. Supraglottic SCC, md T3N2M0 IV 4.0  Surgery 0.9 1.7 6 
S.J. Nasopharynx SCC, nk T4N2M0 IV 3.2  CHT + RT 0.3 1.55 6 
B.A. Base of tongue SCC, md T2N0M0 II 2.25 RT 1.6 2.05 10 
K.Z. Glottis SCC, wd T1N0M0 I 2.1 RT  2.2 2.2 2 
P.G. Glottis SCC, wd T1N0M0 I 0.92 RT  1.65 1.95 0 
V.R. Glottis SCC, wd T1N0M0 I 0.86 RT  1.7 1.7 0 
F.S. Parotid gland SCC, md T3N2M0 IV 6.0  Surgery 1.5 3.9 6 
A.H. Glottis SCC, md T1bN0M0 I 2.5 Surgery 1.8 2.2 1 
K.E. Parotid gland Adenoca. T3N0M0 III 2.2 Surgery + RT 5.8 24 8 
Z.M. Ear SCC, wd T4N0M0 IV 1.3 CHT +RT 1.0 1.0 no elevation 
C.F. Glottis SCC, wd T4N1M0 IV 0.92 Surgery +RT 0.61 1.06 no elevation 
wd – well differentiated, md – moderately differentiated, nk – non-keratinizing, adenoca. – adenocarcinoma, SCC – squamous cell carcinoma, RT –
radiotherapy, CHT – chemotherapy.1700 I Doweck et al
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The finding that Cyfra 21-1 levels may be an independent marker
and the preferred prognostic factor in head and neck cancer may
indicate that this marker reflects tumour mass more accurately
than it does the stage of the disease as expressed by the TNM. This
finding may also have a therapeutic implication, as the tumour
mass is one of the main parameters in deciding a therapeutic
regimen. Since there is no other study on the prognostic value of
Cyfra 21-1 in head and neck cancer, this finding should be care-
fully examined. 
The detection of circulating markers has the potential to serve as
a simple minimally invasive and inexpensive technique for moni-
toring patients for recurrent cancer. In the case of the head and
neck, there is no circulating marker currently available for this
purpose. In the present study, the clinical follow-up of the patients
was accompanied by periodic monitoring of Cyfra 21-1 levels.
83% of the patients with recurrent disease showed elevated Cyfra
21-1 levels before or concomitantly with clinical detection of the
recurrent disease. 77% of patients with no evidence of disease also
had no elevation in the marker level. Previous studies show that
Cyfra 21-1 levels drop to below cut-off levels 24 hours after
successful operation (Ebert et al, 1994; Van der Gaast et al, 1994;
Doweck et al, 1995). According to our findings, re-elevation of the
marker had a positive predictive value of 75% (10 cases of recur-
rence, 2 deaths, 4 NED). These findings are in agreement with the
results reported by Niklinski et al in squamous cell lung cancer
(Niklinski et al, 1996). Similar findings in squamous cell lung
cancer were also reported by Van der Gaast et al (Van der Gaast 
et al, 1994). Currently no other circulating tumour marker is able
to provide similar sensitivity for detecting recurrent cancer of the
head and neck. 
It is important to emphasize that according to this study, 
the marker had a mean lead-time of 4.1 months, in which the
increased marker levels predicted the clinical detection of the
recurrent disease. Two patients with recurrent disease did not
present with elevated marker levels. As reported, they had
nothing in common except low initial levels of Cyfra 21-1. The
absence of elevated Cyfra 21-1 levels, both at diagnosis and 
at recurrence, can be explained by a low tumour mass or 
by the inability of these tumour cells to secrete cytokeratin 19
fragments. 
Elevated levels of Cyfra 21-1 were found in patients who were
treated with radiotherapy during the treatment and up to 2–3
months after completing the treatment. The constant high levels of
Cyfra 21-1 during radiotherapy may indicate continuous cells
damage and tumour necrosis during radiation. Since radiation
affects tumour two months after it is ended, one might expect high
levels of Cyfra 21-1 during this period due to continuous cells
damage. 
As far as we know, in the field of head and neck, there is no
other tumour marker that can provide a similar correlation between
marker levels and the progression of the disease. 
According to our findings, by means of a simple, noninvasive
blood test, Cyfra 21-1 levels provide the head and neck oncologist
with a prognostic tool and an additional monitoring system for
early recognition of the progression of the disease. However, since
the study included a relatively small group of patients, further
investigations encompassing larger patient groups and in a 
particular head and neck cancer sub-site are necessary before the
marker can be used routinely in patients with carcinoma of the
head and neck. 
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